Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Wilner
174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
PLoS ONE
Multidisciplinary
Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
P2.13-04 Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Crizotinib: A Multicenter Cohort Retrospective Study.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared With Chemotherapy in Previously Treated Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations
Journal of Cancer
Oncology